Table 1. Induction immunosuppression.

Citation	Immunosuppressant	N	Methods	Outcomes
Palmer et al. 1999 (7)	ATG vs. no induction	44	Prospective RCT	≥ A2 AR: 23% vs. 55%, P=0.03 BOS: 20% vs. 38% Survival, 1-yr: 68% vs. 73% Survival, 2-yr: 64% vs. 68% No difference in infection or malignancy
Garrity et al. 2001 (8)	Daclizumab vs. no induction	61	Retrospective	≥ A2 AR: 18% vs. 48%, P<0.04 No difference in infection or PTLD
Borro et al. 2005 (9)	Basiliximab vs. no induction	15	Retrospective	AR: 13% vs. 38.5%, P=0.19 BOS: 20% vs.38.5%, P=0.4 Survival, 2-yr: 80% vs. 54%, P=0.14 No difference in infection or malignancy
Hachem et al. 2005 (10)	Basiliximab vs. ATG	157	Retrospective	Cumulative A AR Score higher at 3-, 6-, 12-month with basiliximab, P=0.003, 0.004, 0.033 respectively BOS stage 1 at 2-yr: 36% vs. 26%
Burton et al. 2006 (11)	Daclizumab vs. ATG	335	Retrospective	Freedom from ≥ A2 AR, 3-month: 9% vs. 32% Freedom from ≥ A2 AR, 2-yr: 0% vs. 26% P<0.0001
Mullen et al. 2007 (12)	Daclizumab vs. ATG	50	RCT	No difference in AR or BOS at 1 year Survival: 96% vs. 88%
Ailawadi et al. 2008 (13)	Daclizumab vs. ATG	163	Retrospective	AR: 9% vs. 28%, P=0.002 BOS: 6.4% vs. 23%, P=0.02 Survival: 94% vs. 83%, P=0.05
Hartwig et al. 2008 (14)	ATG vs. no induction	44	Prospective RCT	AR: 62% vs. 68%, P=0.52 Early AR: 5% vs. 41%, P=0.01 Graft survival: 36% vs. 23%, P=0.048
Clinckart et al. 2009 (15)	Basiliximab vs. ATG	37	Retrospective	AR: 52.4% vs. 43.8%

RCT, randomized controlled trial; AR, acute rejection; BOS, bronchiolitis obliterans syndrome; PTLD, posttransplantlymphoproliferative disorder; ATG, anti-thymocyte globulin; yr, year.